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Synthesis of 2-Azaspiro[4.4]nonan-1-ones via Phosphine-catalysed 
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Abstract: The phosphine-catalysed [3+2]-cycloaddition of the 2-methylene γ-lactams 4 and 5 and the 
acrylate 6 with the ylides derived from the ethyl ester, the amide or the chiral camphor sultam derivative 
of 2-butynoic acid (7a-c) give directly, or indirectly after reductive cyclization, spiro-heterocyclic 
products. The acid 32 underwent Curtius rearrangement and then acid hydrolysis to give two novel spiro-
cyclic ketones, 41 and 42. 
 
Key words: phosphine-catalysed, [3+2]-cycloaddition, 2-methylene γ-lactams, spiro-
heterocyclics, Curtius rearrangement. 
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1. Introduction 
 
The 2-azaspiro[4.4]nonan-1-one structure (1) is found in several bioactive natural products, 
including alkaloids, where it forms part of a spiro[cyclopentane-1,1'-[1H]isoindol]-3'(2'H)-one (2) 
or spiro[3H-indole-3,3'-pyrrolidin]-2(1H)-one (3) ring system.1,2  
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We report here a new strategy for the synthesis of both racemic and enantio-enriched versions of the 
2-azaspiro[4.4]nonan-1-one and spiro[cyclopentane-1,1'-[1H]isoindol]-3'(2'H)-one ring systems 
using the phosphine-catalysed [3+2]-cycloaddition of the ethyl ester (7a), the chiral camphor sultam 
(7b) or the amide (7c)  derivative of 2-butynoic acid with either 2-methylene γ-lactams 4 or 5 or the 
acrylate 6, followed by reductive cyclization with zinc (Scheme 1).  Enantiomerically enriched 
versions of 2 can be obtained using or the chiral (1S)-camphor sultam analogue 7b to generate the 
key spiro-heterocyclic system of these target molecules (Scheme 1).  The phosphine-catalysed 
cycloaddition of ethyl buta-2,3-dienoate or ethyl 2-butynoate with electron-deficient alkenes has 
been established as a useful method for preparing substituted cyclopentenes3-13 both in racemic and 
enantio-enriched forms.14  However, only a few examples of preparing spiro-heterocyclic 
derivatives using this method have been reported.7,11-13  During the initial phase of our study, Lu et 
al. reported the triphenylphosphine-catalysed cycloaddition reaction of 4 and 7a.13  
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2. Results and Discussion 
The results of the phosphine-catalysed [3+2]-cycloaddition reactions of the 2-methylene γ-lactams 4 
and 5 with the ylide 8a (X = OEt), that was generated in situ from the reaction of ethyl 2-butynoate 
7a and tributylphosphine (TBP) are shown in Scheme 2. The reaction of 413 with ethyl 2-butynoate 
(2 equiv) and TBP (1 equiv) in benzene solution at RT for 15 h gave a mixture (ca. 80 : 20) of two 
racemic regio-isomeric cycloadducts, 9 and 10, that were isolated in yields of 51 and 21 %, 
respectively, after column chromatography. We found that the use of a stoichiometric amount of 
TBP was required to obtain a good conversion to 9 and 10. The structures of 9 and 10 were 
confirmed by extensive 2D NMR experiments and the structure of 10 was established by single-
crystal X-ray structural analysis (Figure 1).15 The spectroscopic data of these compounds agreed 
well with that reported by Lu et al.,13 who reported a combined yield for 9 and 10 (d. r. = 62 : 38) of 
only 33% when the more hindered and less nucleophilic catalyst, triphenylphosphine (0.1 equiv), 
4 
was employed. Based on steric considerations alone, the regiochemical outcome of this reaction can 
be rationalised as occurring via the transition state A (R = H, X = OEt) which would be expected to 
be favoured over the more sterically demanding transition state B (R = H, X = OEt, Scheme 3).12,13   
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Under similar conditions the chiral 2-methylene γ-lactam 516 reacted with the ylide 8a (X = OEt) to 
produce three cycloadducts, 11, 12 and 13, in a ratio of 63 : 17 : 30, respectively, from 1H NMR 
analysis of the crude reaction mixture (Scheme 2).  Diastereomerically pure samples of 11 (28% 
yield) and 13 (13% yield) could be obtained after extensive purification, however a pure sample of 
12 could not be obtained due to difficulties in separating 12 from 11 and 13.  Although the absolute 
stereochemistries of 11 and 13 could not be unequivocally proven from 2D NMR experiments we 
assume that the major cycloadduct 11 arises from attack of the ylide onto the face of the 2-
methylene group of 5 that is anti to the ethyl ester substituent (via transition state A, R = CO2Et, X 
= OEt, Scheme 3). 
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Figure 1. Molecular projection of 10. 
 
Treatment of ethyl 2-(2-nitrophenyl)propenoate 617 with ethyl 2-butynoate 7a and TBP (0.2 equiv) 
gave the racemic cycloadduct 14 as a single regio-isomer in 93 % yield (Scheme 4). Upon exposure 
to zinc/aqueous HCl, 14 underwent reductive cyclization to give the spiro[cyclopentane-1,1'-
[1H]isoindol]-3'(2'H)-one derivative 15 in 98% yield (Scheme 4).  
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In order to prepare enantiomerically enriched versions of 15, the corresponding cycloaddition 
reaction of 6 with the chiral alkyne 7b, derived from Oppolzer’s (1S)-chiral sultam,18 was examined 
(Scheme 5).  This reaction produced a 3.3 : 1 mixture of the diasteromeric cycloadducts 16 and 17 
from which pure samples could be obtained after column chromatography, along with mixed 
fractions  in a combined yield of 66% (Scheme 5).  The absolute (1S)-configuration of the 
cyclopentane ring of 16 ([α]D26 –22.0 (c 0.3, CHCl3)) was established by a single-crystal X-ray 
structural analysis (Figure 2)15 which then allowed assignment of the 1R-configuration to this ring 
of the minor diastereomer 17 ([α]D24 +19.0 (c 0.6, CHCl3)).  The chiral auxiliary was then removed 
by methanolysis of (S)-16 and (R)-17 in the presence of samarium(III) triflate19 to give the methyl 
esters, (-)-(S)-18 and (+)-(R)-19 in yields of 67% and 68 %, respectively.  Reductive cyclization of 
(-)-(S)-18 or (+)-(R)-19 by treatment with zinc/aqueous HCl gave the tricyclic lactams, (-)-(S)-20 or 
(+)-(R)-21, respectively (Scheme 5). 
 
 
Figure 2. Molecular projection of 16.  
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a Reagents and conditions: (a) Sm(OTf)3 (1 equiv), MeOH, 50°C, 18 h, 67% ((S)-18), 68% ((R)-
19); (b) Zn dust (24 equiv), 8.9M HCl, MeOH/H2O, reflux, 2 h, 69% ((S)-20), 56% ((R)-21). 
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The spiro-cyclic compounds 9, 10 and 15 have three functional groups that can be further 
derivatised to provide compounds with increased structural diversity.  For example, the N-Boc 
protecting group in racemic 9 and 10 was readily removed upon exposure to trifluoroacetic acid 
(TFA) to give compounds 22 and 28, respectively (Scheme 6).  Both compounds gave single 
crystals for X-ray structural analysis (not shown).15 The nitrogen atom of 22 and 28 was readily N-
benzylated with benzyl bromide under basic conditions and the resulting compounds 23 and 29, 
respectively, were converted to the N-aryl amide derivatives 25a,b15 and 31a, respectively, through 
amide bond formation between their respective carboxylic acids, 24 and 3015 and aniline and 4-
dimethylaminoaniline (Scheme 6).   Amide 2715 was obtained from the coupling reaction of aniline 
and the carboxylic acid 26 obtained from base catalysed hydrolysis of ester 22. 
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Scheme 6a (all compounds are racemic)
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31*, R = Bn, X = NHPh
c
d
* Structure confirmed by X-ray  
a Reagents and conditions: (a) TFA, DCM, 2.5 h, 91% (22), 86% (28); (b) NaH (1.3 equiv), Bu4NI 
(0.1 equiv), BnBr (1.5 equiv), dry THF, RT, 1-5 h, 74% (23), 47% (29); (c) K2CO3 (2 equiv), 
MeOH/H2O, high pressure tube, 60°C, 1d, 93% (24), 53% (26), 80% (30); (d) Aniline or 4-N,N-
dimethylaminoaniline (1.2 equiv), HOBT (1 equiv), EDCI (1 equiv), dry MeCN, 0°C60°C, 1-2d, 
54% (25a), 64% (25b), 91% (27), 91% (31a). 
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Using related chemistry, the ester 15 was converted to the N-aryl amides 33a,b via the carboxylic 
acid 32 (Scheme 7).   
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a; Ar = Ph, b; Ar = 4-Me2NC6H4-
Scheme 7a (all compounds are racemic)
 
a Reagents and conditions: (a) K2CO3 (2 equiv), MeOH/H2O, high pressure tube, 60°C, 5 h, 94%; 
(b) Aniline or 4-N,N-dimethylaminoaniline (1.7 equiv), HOBT (1 equiv), EDCI (1 equiv), MeCN, 
0°CRT, 15 h, 92% (33a), 44% (33b). 
 
To explore a more direct method to these N-aryl amide derivatives, the phosphine-catalysed [3+2]-
cycloaddition reactions of the 2-methylene γ-lactam 4 and acrylate 6 with the ylide 8 (X = NHPh), 
that was generated in situ from the reaction of N-phenyl 2-butynamide 34, was examined (Schemes 
8 and 9).  These reactions were unsuccessful, presumably due to internal quenching of the ylide 8 
(X = NHPh) by the relatively acidic secondary amide NH.  In accordance with this hypothesis was 
the fact that the corresponding N-PMB protected ylide 8c (X = N(PMB)Ph), generated in situ from 
the tertiary amide 7c, gave the racemic cycloadducts 35 and 36, in yields of 14% and 55%, 
respectively (Schemes 8 and 9).  These reactions, while poor to modest in yields, were completely 
regioselective, presumably due to the increased steric bulk of the ylide 8c which would further 
destabilize transition state B over transition state A (Scheme 3).  Treatment of the cycloladdition 
product 35 with TFA, gave N-phenyl amide 27 (Scheme 8) that was identical to the compound 27 
prepared according to Scheme 6. Similarly, reductive cyclization of 36 followed by deprotection of 
12 
the product 37 with TFA gave 33a (Scheme 9) that was identical to the compound 33a prepared 
according to Scheme 7. To the best of our knowledge the phosphine-catalysed [3+2]-cycloaddition 
reactions of alkenes and 2-butynamides has not been previously reported.      
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a Reagents and conditions: (a) Anisole (10 equiv), TFA (125 equiv), DCM, 15 h, 57%.  
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a Reagents and conditions: (a) Activated Zn dust (3.4 equiv), acetic acid, 1.5 h, 16%; (b) Anisole 
(10 equiv), TFA (125 equiv), DCM, 15 h, 52%.  
 
With the aim of preparing the novel spiro-cyclic ketone 41, the racemic carboxylic acid 32 
was converted to the corresponding acyl azide by treatment with diphenylphosphoryl azide 
(DPPA),20 which was then heated under Curtius rearrangement conditions.  Acid hydrolysis of the 
resulting product mixture gave ca a 1 : 1 mixture of the spiro-cyclic ketones 41 and 42 (Scheme 10). 
These compounds were readily separated by column chromatography and were isolated in yields of 
54% and 35%, respectively.  The 1H NMR spectrum of 42 showed two distinct N-H resonances 
(δΗ (C6D6) 7.96 (bs), 4.84 (bs)) and a deshielded aromatic proton (δΗ (C6D6) 8.64 (d, J 8 
Hz), consistent with the presence of the N-aminocarbonyl group with internal H-bonding to the 
lactam carbonyl group.  The structures of 41 and 42 were confirmed by a single crystal X-ray 
structural analysis (42: Figure 3).15 We assume that the unexpected product 42 arises from self-
condensation of the intermediate vinyl isocyanate 38 to give the carbamate derivative 39.  Acid 
14 
hydrolysis of 39 then gives, via 40, the spiro-cyclic ketones 41 and 42 (Scheme 10).  We have not 
however attempted to isolate or characterize the intermediates involved. 
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Figure 3. Molecular projection of 42. 
 
Catalytic hydrogenation of the alkene moiety of racemic 15 gave a 1.8 : 1 mixture of the 
diastereomers 43 and 44, respectively that were readily separated by column chromatography 
(Scheme 11).  The relative stereochemistry of 43 was determined by 1D NOE experiments that 
showed a significant enhancement of the signal for the methine proton Ha upon radiation of the 
aromatic proton Hb and vice versa.   
N
H
O
CO2Et
N
H
O
CO2Et
Ha
Hb
N
H
O
CO2Et
H
Pd/C
H2
EtOAc
15 43 (57%)
* NOE
Scheme 11 (all compounds are racemic)
44 (20%)
+
*
 
 
3. Cytotoxicity Studies 
Compounds 15, 25a,b, 27, 31, 33a,b, 41, 42, 43 and 44 were all tested for their cytotoxic activity 
against the cancer cell lines H460 (human non small cell lung), MCF-7 (human breast) and SF-268 
(human CNS) at the Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne, Vic, 
3002, Australia. Biological testing was performed using standard NCI procedures at a drug 
concentration of 25 µM (5 mM drug stocks were prepared in DMSO. Cells were then exposed to 25 
µM of each drug for 72 h. The cells were then fixed, stained with SRB and the percentage cell 
16 
growth relative to the solvent control determined). Percent cell growth calculated from this testing 
showed little or no cytotoxic activity. The best activity was 50% cell growth at 25 µM for 33b 
against H460.  
 
In conclusion, we have developed a new strategy for the synthesis of both racemic and enantio-
enriched versions of the 2-azaspiro[4.4]nonan-1-one and spiro[cyclopentane-1,1'-[1H]isoindol]-
3'(2'H)-one ring systems using the phosphine-catalysed [3+2]-cycloaddition of both ester (7a) and 
amide derivatives (7c) of 2-butynoic acid. Enantiomerically enriched versions of 2 can be obtained 
using a chiral (1S)-camphor sultam derivative 7b of 2-butynoic acid.  We have also demonstrated 
the potential of these compounds as scaffolds for developing libraries of novel spiro-heterocyclic 
compounds.  
 
4.  Experimental 
For X-ray structure determinations see supporting information. All 1H NMR spectra were performed 
at 300 MHz and all 13C NMR (DEPT) spectra at 75 MHz in CDCl3 solution, unless otherwise 
noted. Abbreviations:  PS (petroleum spirit, bp 40-60°C) and DCM (dichloromethane). 
 
Ethyl (5S*) 2-(tert-butoxycarbonyl)-1-oxo-2-azaspiro[4.4]non-7-ene-7-carboxylate (9) and 
Ethyl (5R*) 2-(tert-butoxycarbonyl)-1-oxo-2-azaspiro[4.4]non-6-ene-6-carboxylate (10) 
To a solution of 4 (200.7 mg, 1.02 mmol) in dry benzene (3 mL) was added ethyl 2-butynoate (0.13 
mL, 1.12 mmol) and tributylphosphine (0.25 mL, 1.01 mmol). The reaction mixture was allowed to 
stir at RT for 15 h, under an atmosphere of N2. The solvent was then evaporated in vacuo. An 82:18 
mixture of the two regioisomers, 9 and 10 respectively, resulted (determined from analysis of the 1H 
NMR spectrum of the crude reaction product). Compounds 9 and 10 were purified by column 
chromatography using 10-30% EtOAc:PS as the eluent. These compounds were further purified by 
PTLC (30% EtOAc:PS). 9: A yellow oil (161.7 mg, 0.52 mmol, 51%), Rf 0.78 (30% EtOAc:PS). 1H 
NMR (C6D6, 500 MHz) δ 6.37 (t, J 2 Hz, 1H, CH=), 3.98 (dd, J 14, 7.5 Hz, 2H, CH2CH3), 3.20 
17 
(ddd, J 13, 6, 6 Hz, 2H, NCH2), 3.04 (dq, J 16.5, 2.5 Hz, 1H, CH-6β), 2.71 (dq, J 18.5, 2.5 Hz, 1H, 
CH-9β), 2.13 (d, 16.5 Hz, 1H, CH-6α), 1.73 (d, 18 Hz, 1H, CH-9α), 1.48 (s, 9H, C(CH3)3), 1.12 
(ddd, J 13, 6, 6 Hz, 1H, CHACHB-4), 1.04 (ddd, J 13, 6, 6 Hz, 1H, CHACHB-4), 0.97 (t, 7.5Hz, 3H, 
CH3CH2). 13C NMR (C6D6, 75 MHz) δ 175.4 (C-1), 163.7 (CO2Et), 151.0 (NCO2), 139.8 (CH=), 
134.3 (C-7), 82.1 (C(CH3)3), 60.1 (CH2CH3), 51.6 (C-5), 43.3 (CH2-9), 42.9 (NCH2), 42.3 (CH2-6), 
33.2 (CH2-4), 28.1 (C(CH3)3), 14.3 (CH3CH2). MS (ES) m/z 348 ([M+ +K], 15%), 332.1 ([M+ +Na], 
60%), 310.0 ([MH+], 32%), 254.1 ([MH+ -C(CH3)3], 100%), 210.1 ([MH+ -Boc], 85%); HRMS (CI) 
Calcd for C16H24NO5 [MH+] 310.1654. Found: 310.1664. NMR data for 9 agreed well with 
literature when performed under the literature conditions.13 10: A white crystalline solid (44.3 mg, 
0.14 mmol, 21%), mp. 100-102°C (lit.13 107-110.5°C), Rf 0.58 (30% EtOAc:PS). 1H NMR (500 
MHz) δ 6.99 (t, J 2.5 Hz, 1H, CH=), 4.17 (ddd, J 14.5, 7, 0.5 Hz, 2H, CH2CH3), 3.90 (ddd, 10.5, 
9.5, 3.5 Hz, 1H, NCHACHB), 3.63 (ddd, J 10.5, 8.5, 8.5 Hz, 1H, NCHBCHA), 2.62-2.69 (m, 1H, 
CHACHB-8), 2.51-2.58 (m, 1H, CHBCHA-8), 2.38-2.46 (om, 2H, CHACHB-9 and CHACHB-4), 1.98 
(ddd, J 13, 8.5, 4.5 Hz, 1H, CHBCHA-9), 1.92 (ddd, J 12.5, 8.5, 4 Hz, 1H, CHBCHA-4), 1.54 (s, 9H, 
(C(CH3)3), 1.26 (dt, J 7.5, 2.5 Hz, 3H, CH3CH2). 13C NMR δ 176.8 (C-1), 163.6 (CO2Et), 150.6 
(NCO2), 147.5 (CH=), 138.0 (C-6), 83.0 (C(CH3)3), 60.8 (CH2CH3), 59.7 (C-5), 44.2 (NCH2), 37.4 
(CH2-9), 31.7 (CH2-8), 29.8 (CH2-4), 28.4 (C(CH3)3), 14.5 (CH3CH2). MS (ES) m/z 310.2 ([MH+], 
53%), 332.1 ([M++Na+], 29%), 348.1 ([M++K+], 23%), 254.1 ([MH+-C(CH3)3], 100%), 209.8 ( 
[MH+-Boc], 95%); HRMS (ES) Calcd for C16H24NO5 [MH+] 310.1654. Found: 310.1654. The 
NMR data collected for 10 agreed well with those found in literature.13  
 
2-tert-Butyl 3,7-diethyl (3S,5S)-1-oxo-2-azaspiro[4.4]non-7-ene-2,3,7-tricarboxylate (11) and 2-
tert-butyl 3,7-diethyl (3S,5R)-1-oxo-2-azaspiro[4.4]non-7-ene-2,3,7-tricarboxylate (13) 
To a solution of 5 (125.8 mg, 0.47 mmol) in dry benzene (3 mL) was added ethyl-2-butynoate (0.06 
mL, 1.12 mmol) and tributylphosphine (0.25 mL, 1.01 mmol). The reaction was allowed to stir at 
RT for 15 h, under an atmosphere of N2. The solvent was evaporated in vacuo and 1H NMR analysis 
18 
showed a mixture of the two diastereomers, 11 and 12, and one regioisomer 13 (11:12:13 = 
63:17:30). Compounds 11 and 13 were purified by column chromatography using 20-90% 
EtOAc:PS as eluent and further by PTLC (30% EtOAc:PS). A pure sample of 12 was unable to be 
isolated.  11: A yellow oil (50.5 mg, 0.13 mmol, 28%), [α]D22 -17.5 (c 4.6, CHCl3), Rf  0.57 (30% 
EtOAc:PS). 1H NMR (500 MHz) δ 6.57 (s, 1H, CH=), 4.54 (dd, J 9.5, 4.5 Hz, 1H, CH-5), 4.21 (dq, 
J 6.5, 1.5 Hz, 2H, NCHCO2CH2), 4.16 (q, J 6.7 Hz, 2H, CCO2CH2), 3.15 (dd, J 16.5, 2 Hz, 1H, 
CH-6β), 3.04 (dd, J 18.5, 1.5 Hz, 1H, CH-9β), 2.55 (d, J 16.5 Hz, 1H, CH-6α), 2.39 (d, J 17.5 Hz, 
1H, CH-9α), 2.33-2.55 (m, 1H, CHACHB-4), 2.09 (dd, J 13, 4 Hz, 1H, CHBCHA-4), 1.49 (s, 9H, 
C(CH3)3), 1.23-1.29 (m, 6H, CH2CH3). 13C NMR δ 176.9 (C-1), 171.5 (NCHCO2Et), 164.3 
(CCO2Et), 149.6 (NCO2) 139.8 (CH=), 134.4 (C-7), 84.0 (C(CH3)3), 61.9 (NCHCO2CH2), 60.7 
(CCO2CH2), 56.7 (CH-5), 51.0 (C-3), 45.2 (CH2-9), 43.5 (CH2-6), 37.9 (CH2-4), 28.1 (C(CH3)3), 
14.4 (CH3CH2), 14.3 (CH3CH2). MS (ES) m/z 382.2 ([MH+], 5%); HRMS (ES) Calcd for 
C19H28NO7 [MH+] 382.1866. Found: 382.1892. 13: A yellow oil (24 mg, 63 μmol, 13%), [α]D23 -
1.88 (c 0.14, CHCl3), Rf 0.36 (30% EtOAc:PS). 1H NMR (500 MHz) δ 6.65 (s, 1H, CH=), 4.57 (dd, 
J 9.5, 3.5 Hz, 1H, CH-5), 4.21-4.29 (m, 2H, NCHCO2CH2), 4.18 (q, J 7.5 Hz, 2H, CCO2CH2), 
3.12-3.17 (m, 1H, CH-6β), 3.08-3.12 (m, 1H, CH-9β), 2.51 (d, J 16.5 Hz, 1H, CH-6α), 2.45 (d, J 
18.5 Hz, 1H, CH-9α), 2.33 (dd, J 13.5, 9.5 Hz, 1H, CHACHB-4), 2.20 (dd, J 13.5, 4 Hz, 1H, 
CHBCHA-4), 1.51 (s, 9H, C(CH3)3), 1.31 (t, J 7Hz, 3H, CCO2CH2CH3), 1.27 (t, J 7 Hz, 3H, 
NCHCO2CH2CH3). 13C NMR δ 177.0 (C-1), 171.1 (NCHCO2Et), 164.3 (CCO2Et), 149.4 (NCO2), 
139.9 (C-8), 133.8 (C-7), 83.8 (C(CH3)3), 61.8 (NCHCO2CH2), 60.4 (CCO2CH2), 56.4 (CH-5), 50.7 
(C-3), 44.8 (CH2-9), 43.6 (CH2-6), 37.8 (CH2-4), 27.8 (C(CH3)3), 14.2 (CH3CH2), 14.1 (CH3CH2). 
MS (ES) m/z 382.2 ( [MH+], 5%); HRMS (ES) Calcd for C19H28NO7 [MH+] 382.1866. Found: 
382.1914. 
 
3-Ethyl, 1-methyl 1-(2-Nitrophenyl)-cyclopent-3-ene-1,3-dicarboxylate (14) 
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To a solution of alkene 6 (1.013 g, 4.9 mmol) and ethyl 2-butynoate (0.63 mL, 5.4 mmol) in dry 
benzene (35 mL) was slowly added tributylphosphine (0.24 mL, 0.98 mmol). The reaction was left 
to stir for 6 h. Upon evaporation in vacuo of volatiles, the resulting crude product was purified by 
column chromatography using 20-50% EtOAc:PS as eluent to yield a peach coloured oil (1.45 g, 
4.5 mmol, 93%), Rf 0.81 (50% EtOAc:PS). 1H NMR δ 7.93 (dd, J 8.1, 1.5Hz, 1H, ArH-3), 7.58 (dt, 
J 7.8, 1.8 Hz, 1H, ArH-5), 7.42 (dt, J 7.6, 1.5 Hz, 1H, ArH-4), 7.40 (d, 7.8Hz, 1H, ArH-6), 6.74 (t, J 
1.8 Hz, 1H, CH=), 4.20 (q, J 6.9 Hz, 2H, CH2CH3), 3.64 (s, 3H, CO2CH3), 3.62 (dq, J 19.2, 2.7 Hz, 
1H, CH-5`α), 3.52 (dq, J 17.4, 2.5 Hz, 1H, CH-2`α), 3.21 (dm, J 17.1 Hz, 1H, CH-2`β), 2.99 (dt, J 
19.2, 2.4 Hz, 1H, CH-5`β),1.29 (t, J 6.9 Hz, 3H, CH3CH2). 13C NMR δ 174.0 (CO2Me), 164.0 
(CO2Et), 148.1 (ArC-2), 140.1 (CH=), 138.1 (ArC-1), 133.8 (C-3`), 133.2 (ArCH-5), 128.3 (ArCH-
6), 128.0 (ArCH-4), 125.3 (ArCH-3), 60.6 (CH2CH3), 55.6 (C-1`), 52.4 (CO2CH3), 45.8 (CH2-5`), 
44.2 (CH2-2`), 14.2 (CH2CH3). MS (CI) m/z C16H18NO6 320 ([MH+], 100%), 288 ([MH+ - Et], 
41%), 206 (68%), 246 (22%), 188 (21%); HRMS (CI) Calcd for C16H18NO6 [MH+] 320.1134. 
Found: 320.1132. 
 
Ethyl 2-oxo-spiro[3`-cyclopentene-1`,3-[3H]indole]-3`-carboxylate (15)  
To a solution of 14 (29.5 mg, 0.092 mmol) in EtOH (0.7 mL) and H2O (0.18 mL) was added 
activated Zn dust (96 mg, 1.5 mmol) and 8.9M HCl (0.14 mL). The reaction was heated at reflux for 
2 h. Another portion of activated Zn dust (96 mg, 1.5 mmol) was added and the reaction was left at 
reflux for an additional 4 h. The mixture was then filtered through celite and diluted with H2O. The 
filtrate was then extracted with EtOAc and the organic extracts were combined and dried over 
MgSO4 to yield a creamy brown oil (23.4 mg, 0.091 mmol, 98%), Rf 0.5 (50% EtOAc:PS). 1H 
NMR (500 MHz) δ 9.15 (bs, 1H, NH), 7.21 (d, J 7.5 Hz, 1H, ArH-4), 7.20 (t, J 8 Hz, 1H, ArH-6), 
7.01 (t, J 7.7 Hz, 1H, ArH-5), 6.93 (d, J 8 Hz, 1H, ArH-7), 6.86 (bs, 1H, CH=), 4.23 (q, J 7Hz, 2H, 
CH2CH3), 3.27 (dd, J 16.5, 2.5 Hz, 1H, CH-2`α), 3.19 (dd, J 18.7, 2.25 Hz, 1H, CH-5`α), 2.90 (d, J 
16.5 Hz, 1H, CH-2`β), 2.80 (d, J 18.5 Hz, 1H, CH-5`β), 1.31 (t. J 7.25 Hz, 3H, CH3CH2). 13C NMR 
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δ 183.2 (C-2), 164.2 (CO2Et), 140.6 (CH=), 139.7 (C-7a), 136.6 (C-3a), 134.8 (C-3`), 128.1 (ArCH-
6), 123.0 (ArCH-5), 122.1 (ArCH-4), 109.9 (ArCH-7), 60.5 (CH2CH3), 52.5 (C-3), 44.9 (CH2-5`), 
43.4 (CH2-2`), 14.2 (CH3CH2). MS (CI) m/z 258 ([MH+], 100%), 212 ([M+-OEt], 12%), 184 ( [M+-
CO2Et], 12%); HRMS (EI) Calcd for C15H15NO3 [M+] 257.1052. Found: 257.1048. 
 
(3aS,6R,7aR,4’S)-Hexahydro-4’-methoxycarbonyl-4’-(2’’-nitrophenyl)-1’-(cyclopenten-1’-
ylcarbonyl)-8,8-dimethyl-2,2-dioxide-3H-3a,6-methano-2,1-benzisothiazole ((S)-16) and 
(3aS,6R,7aR,4’R)-Hexahydro-4’-methoxycarbonyl-4’-(2’’-nitrophenyl)-1’-(cyclopenten-1’-
ylcarbonyl)-8,8-dimethyl-2,2-dioxide-3H-3a,6-methano-2,1-benzisothiazole ((R)-17) 
To a solution of 6 (147 mg, 0.709 mmol) and 7b (198 mg, 0.706 mmol) in dry benzene (1.5 mL) 
under a N2 atmosphere was added tributylphosphine (0.02 mL, 71 µmol). The reaction was stirred at 
RT for 18 h and then the solvent was removed in vacuo. The diastereomeric products were obtained 
in a ratio of 3.3:1 ((S)-16):(R)-17) from 1H NMR analysis of the crude reaction mixture. The crude 
mixture was purified by column chromatography using 15% EtOAc:PS as eluent, yielding pure 
diastereomeric products (S)-16) (140.6 mg, 0.29 mmol, 13%) and (R)-17 (154 mg, 0.32 mmol, 
15%) and a mixture (400 mg, 0.82 mmol, 38%) containing both diastereomeric products in a ratio 
of 4.3:1 ((S)-16):(R)-17). Further purification by PTLC (20% EtOAc:PS) could yield the pure 
diastereomeric products. (S)-16: A colourless crystal, mp. 196-200 oC, [α]D26 -22.0 (c 0.3, CHCl3), 
Rf 0.53 (30% EtOAc:PS). 1H NMR (500 MHz) δ 7.94 (d, J 7.5 Hz, 1H, ArH-3’’), 7.56 (bs, 2H, 
ArH-5’’, ArH-6’’), 7.41 (bs, 1H, ArH-4’’), 6.74 (bs, 1H, CH=), 4.07 (t, J 5.5 Hz, 1H, CH-7a), 3.74 
(d, J 19.5 Hz, 1H, CH-3’α), 3.66 (s, 3H, CO2CH3), 3.64 (d, J 19.0 Hz, 1H, CH-5’α), 3.45 (ABq, J 
13.5 Hz, 2H, CH2-3), 3.19 (d, J 19.0 Hz, 1H, CH-5’β), 3.06 (d, J 19.5 Hz, 1H, CH-3’β), 2.09-1.99 
(m, 2H, H-7α, CH-7β), 1.97-1.91 (m, 3H, CH-4β, CH-5β, CH-6), 1.44-1.37 (m, 2H, CH-4α, CH-5α), 
1.24 (s, 3H, CH3-9), 1.00 (s, 3H, CH3-10). 13C NMR (125 MHz) δ 174.8 (CO2Me), 171.3 (=CCO), 
148.5 (ArC-2’’), 141.6 (CH=), 138.4 (ArC-1’’) 134.7 (C-1’), 133.4 (ArCH-5’’), 129.2 (ArCH-6’’), 
128.0 (ArCH-4’’), 125.1 (ArCH-3’’), 65.6 (CH-7a), 54.6 (C-4’), 53.7 (CH2-3), 52.4 (CO2CH3), 48.1 
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(C-3a), 47.7 (C-8), 47.0 (CH2-3’), 45.5 (CH2-5’), 45.2 (CH-6), 38.3 (CH2-7), 33.3 (CH2-4), 26.5 
(CH2-5), 21.3 (CH3-9), 19.9 (CH3-10). LRMS (EI) m/z 488 ([M+], 5%); HRMS (CI) Calcd for 
C24H29N2O7S [MH+] 489.1695. Found: 489.1690. (R)-17: A colourless crystal, mp. 198-202 oC, 
[α]D24 +19.0 (c 0.6, CHCl3), Rf 0.43 (30% EtOAc:PS). 1H NMR (500 MHz) δ 7.95 (d, J 8.0 Hz, 1H, 
ArH-3’’), 7.60 (t, 7.5 Hz, 1H, ArH-5’’), 7.54(d, J 8.0 Hz, 1H, ArH-6’’), 7.43 (t, 7.5 Hz, 1H, 
ArH4’’), 6.66 (s, 1H, CH=), 4.07 (m, 1H, CH-7a), 3.80 (d, J 19.0 Hz, 1H, CH-3’β), 3.68 (s, 3H, 
CO2CH3), 3.50 (d, J 13.5 Hz, 1H, CH-3A), 3.46-3.42 (m, 3H, CH-5’β, CH-5’α, CH-3B), 2.97 (d, J 
19.0 Hz, 1H, CH-3’α), 2.06-2.00 (m, 2H, CH-7α, CH-7β), 1.98-1.90 (m, 3H, CH-4β, CH-5β, CH-6), 
1.42 (m, 2H, CH-4α, CH-5α), 1.23 (s, 3H, CH3-9), 1.00 (s, 3H, CH3-10). 13C NMR (125 MHz) δ 
173.9 (CO2Me), 165.7 (=CCO), 148.2 (ArC-2’’), 139.9 (CH=), 138.1 (ArC-1’’), 134.7 (C-1’), 133.3 
(ArCH-5’’), 128.6 (ArCH-6’’), 128.0 (ArCH-4’’), 125.4 (ArCH-3’’), 65.5 (CH-7a), 55.9 (C-4’), 
53.6 (CH2-3), 52.5 (CO2CH3), 48.1 (C-3a), 47.7 (C-8), 46.3 (CH2-3’), 44.8 (CH2-5’), 45.2 (CH-6), 
38.4 (CH2-7), 33.2 (CH2-4), 26.5 (CH2-5), 21.3 (CH3-9), 19.9 (CH3-10). MS (EI) m/z 488 ([M+], 
2.6%); HRMS (CI) Calcd for C24H29N2O7S [MH+] 489.1695. Found: 489.1713. 
 
 
Dimethyl (1S)-1-(2’-nitrophenyl)-3-cyclopentene-1,3-dicarboxylate ((S)-18) 
To a solution of (S)-16 (199 mg, 0.4 mmol) in dry MeOH (10.2 mL) was added Sm(OTf)3 (258 mg, 
0.43 mmol). The reaction was heated at 50 oC for 15 h. The mixture was then cooled and the solvent 
was removed in vacuo. The residue was then diluted with DCM. The mixture was then washed with 
brine and sat. NaHCO3, dried and solvent removed in vacuo. The crude mixture was purified by 
column chromatography using 8:11:1 (DCM:PS:EtOAc) as eluent to afford (S)-18 as a peach oil 
(82.4 mg, 0.27 mmol, 67%) and the recovered chiral auxiliary as white crystals. (S)-18: [α]D24 -42.5 
(c 0.1, CHCl3), Rf 0.42 (20% EtOAc:PS). 1H NMR δ 7.95 (dd, J 7.8, 1.5 Hz, 1H, ArH-3’), 7.59 (dt, 
J 7.5, 1.5 Hz, 1H, ArH-5’), 7.44 (dt, J 7.5, 1.5 Hz, 1H, ArH-4’), 7.42 (dd, J 7.8, 1.5 Hz, 1H, ArH-
6’), 6.76 (m, 1H, CH=), 3.77 (s, 3H, =CCO2CH3), 3.67 (s, 3H, PhCCO2CH3), 3.62 (dddd, J 19.5, 
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5.1, 5.1, 2.7 Hz, 1H, CH-5α), 3.51 (dddd, J 17.4, 5.1, 5.1, 2.4 Hz 1H, CH-2α), 3.22 (dt, J 17.1, 1.5 
Hz, 1H, CH-2β), 2.98 (dddd, J 19.1, 2.4, 2.4, 0.9 Hz, 1H, CH-5β). 13C NMR (125 MHz) δ 174.0 
(PhCCO2Me), 164.4 (=CCO2Me), 148.2 (ArC-2’), 140.4 (CH=), 138.0 (ArC-1’), 133.6 (C-3), 133.2 
(ArCH-5’), 128.3 (ArCH-6’), 128.1 (ArCH-4’), 125.3 (ArCH-3’), 55.7 (C-1), 52.4 (PhCCO2CH3), 
51.7 (=CCO2CH3), 45.8 (CH2-5), 44.2 (CH2-2). MS (ES) m/z 306 ([MH+], 13%); HRMS (ES) 
Calcd for C15H16NO6 [MH+] 306.0978. Found: 306.0966. 
 
Dimethyl (1R)-1-(2’-nitrophenyl)-3-cyclopentene-1,3-dicarboxylate ((R)-19) 
The title compound was prepared using a similar method to that described above for the synthesis of 
(S)-18 using (R)-17 (81.9 mg, 0.17 mmol). Purification by column chromatography in solvent 
system 8:11:1 (DCM:PS:EtOAc) gave (R)-19 as a brown oil (34.7 mg, 0.1 mmol, 68%) and 
recovered chiral auxiliary as white crystals. (R)-19: [α]D26 +50.0 (c 0.7, CHCl3), Rf = 0.26 in 20% 
EtOAc:PS). MS (ES+ve) m/z 306 (26%) [MH+]; HRMS (ES+ve) Calcd for C15H16NO6 [MH+] 
306.0978. Found: 306.0984. The 1H NMR spectrum of (R)-19 was identical to that of its 
enantiomer (S)-18. 
 
Methyl (1’S)-2-Oxo-spiro[3’-cyclopentene-1’,3-[3H]indole]-3’-carboxylate (S)-20)  
To a solution of (S)-18 (21.7 mg, 0.07 mmol) in MeOH (0.5 mL) and H2O (0.17 mL) was added 
activated Zn dust (112 mg, 1.7 mmol) and 8.9 M HCl (0.1 mL). The reaction was heated at reflux 
for 2 h. The mixture was then cooled and filtered through celite, washing precipitate with H2O and 
MeOH. The filtrate was evaporated in vacuo. The crude product was purified by column 
chromatography using 30% EtOAc:PS as eluent and further purified by PTLC (30% EtOAc:PS). 
(S)-20 was obtained as a yellow oil (11.9 mg, 0.049 mmol, 69%), [α]D24 -40.8 (c 1.2, CHCl3), Rf 
0.23 (30% EtOAc:PS). 1H NMR δ 8.73 (bs, 1H, NH), 7.21 (dd, J 7.5, 1.2 Hz, 1H, ArH-4), 7.20 (td, 
J 7.8, 1.2 Hz, 1H, ArH-6), 7.01 (td, J 7.8, 0.9 Hz, 1H, ArH-5), 6.92 (d, J 7.8 Hz, 1H, ArH-7), 6.88-
6.84 (m, 1H, CH-4’), 3.79 (s, 3H, CH3), 3.26 (ddd, J 18.3, 5.1, 2.7, 2.4 Hz, 1H, CH-2’α), 3.20 (ddd, 
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J 20.3, 5.1, 2.7, 2.4 Hz, 1H, CH-5’α ), 2.90 (ddd, J 18.3, 2.4, 1.5 Hz, 1H, CH-2’β), 2.80 (m, 1H, CH-
5’β). 13C NMR δ 182.9 (C-2), 164.6 (CO2Me), 140.9 (CH=), 139.7 (C-7a), 136.5 (C-3a), 134.5 (C-
3’), 128.1 (ArCH-6), 123.0 (ArCH-5), 122.2 (ArCH-4), 109.8 (ArCH-7), 52.5 (C-3), 51.7 (CH3), 
45.0 (CH2-5’), 43.4 (CH2-2’). MS (EI) m/z 243 ([M+], 11%); HRMS (ES) Calcd for C14H14NO3 
[MH+] 244.0974. Found: 244.0966. 
 
Methyl (1’R)-2-Oxo-spiro[3’-cyclopentene-1’,3-[3H]indole]-3’-carboxylate ((R)-21)  
The title compound was prepared using a similar method to that described above for the synthesis of 
(S)-20 using (R)-19 (14.6 mg, 0.048 mmol). (R)-21 was obtained as a peach oil (6.5 mg, 0.027 
mmol, 56%), [α]D23 +57.4 (c 1.0, CHCl3), Rf 0.52 (30% EtOAc:PS). The 1H NMR spectrum of (R)-
21 was identical to that of (S)-20. MS (EI) m/z 243 ([M+], 50%); HRMS (ES) Calcd for C14H14NO3 
[MH+] 244.0974. Found: 244.0963. 
 
Ethyl (5S*)-1-oxo-2-azaspiro[4.4]non-7-ene-7-carboxylate (22) 
To a solution of 9 (852.4 mg, 2.76 mmol) in dry DCM (2.5 mL), was added TFA (2.5 mL). The 
solution was left to stir for 2.5 h under an atmosphere of N2. The solvent was removed in vacuo, and 
the oily residue was then treated with saturated NaHCO3 solution (2 × 10 mL) and extracted with 
DCM (2 × 20 mL). The organic portions were dried, and evaporated in vacuo to yield 22 as brown 
needle-like crystals (524.2 mg, 2.5 mmol, 91%), mp. 70-78 °C, Rf 0.26 (70% EtOAc:PS). 1H NMR 
δ 7.50 (bs, 1H, NH), 6.69 (t, J 2.7 Hz, 1H, CH=), 4.19 (q, J 7.2 Hz, 2H, CH2CH3), 3.35 (t, J 7.1 Hz, 
2H, NCH2), 3.02 (od, J 16.5, 2H, CH-6β, CH-9β), 2.59 (d, J 15.9 Hz, 1H, CH-6α), 2.46 (d, J 18.9 
Hz, 1H, CH-9α), 2.14-2.16 (m, 2H, CH2-4), 1.32 (t, J 7.0  3H, CH2CH3). 13C NMR δ 182.35 (C-1), 
164.65 (CO2Et), 140.9 (CH=), 134.5 (C-7), 60.4 (CH2CH3), 49.4 (C-5), 43.5 (CH2-9), 42.0 (CH2-6), 
39.5 (NCH2), 37.8 (CH2-4), 14.4 (CH2CH3). MS (CI) m/z 210 ([MH+], 100%); HRMS (CI) Calcd 
for C11H16NO3 [MH+] 210.1130. Found: 210.1132. 
 
24 
Ethyl (5S*)-2-benzyl-1-oxo-2-azaspiro[4.4]non-7-ene-7-carboxylate (23) 
To a stirred solution of 22 (255.7 mg, 1.22 mmol) in dry THF (15 mL), under an atmosphere of N2, 
was added in quick succession, NaH (76 mg, 1.6 mmol, 50% dispersion in paraffin oil), 
tetrabutylammonium iodide (45 mg, 0.12 mmol) and benzyl bromide (0.22 mL, 1.85 mmol). The 
reaction mixture was left stirring for 1 h. The reaction mixture was then quenched with H2O (50 
mL) and extracted with DCM (3 × 40 mL). The combined organic extracts were then dried and 
evaporated in vacuo. The crude product was purified by column chromatography using 40-60% 
EtOAc:PS as the eluent to give 23 as a brown oil (271.5 mg, 0.91 mmol, 74%), Rf 0.56 (50% 
EtOAc:PS). 1H NMR δ 7.21-7.34 (m, 5H, ArH), 6.69 (s, 1H, CH=), 4.46 (ABq, J 14.5 Hz, 2H, 
NCHACHBPh), 4.19 (dq, J 6.9, 2.4 Hz, 2H, CH2CH3), 3.16-3.21 (m, 2H, CH2-3), 3.05 (od, J 16.2 
Hz, 2H, CH-6β, CH-9β), 2.56 (d, J 15.3 Hz, 1H, CH-6α), 2.43 (d, J 18.9 Hz, 1H, CH-9α), 1.91-2.04 
(m, 2H, CH2-4), 1.28 (dt, J 2.4, 7.2 Hz, 3H, CH2CH3). 13C NMR δ 178.0 (C-1), 164.6 (CO2Et), 
141.0 (CH=), 136.6 (C-7), 134.4 (ArC-i), 128.9 (ArCH-m), 128.2 (ArCH-o), 127.8 (ArC-p), 60.5 
(CH2CH3), 50.3 (C-5), 47.1 (NCH2Ph), 43.81 (CH2-9), 43.78 (CH2-3), 42.2 (CH2-6), 35.5 (CH2-4), 
14.5 (CH2CH3). MS (CI) m/z 300 ([MH+], 8%); HRMS (EI) Calcd for C18H21NO3 [M+] 299.1521. 
Found: 299.1508. 
 
(5S*)-2-Benzyl-1-oxo-2-azaspiro[4.4]non-7-ene-7-carboxylic acid (24)  
A solution of a 23 (271.5 mg, 0.91 mmol) in MeOH (2 mL) contained within a sealed tube was 
added a solution of K2CO3 (251 mg, 1.82 mmol) in water (2.5 mL). The mixture was left stirring at 
40°C for 4d, another equivalent of K2CO3 was added and temperature was raised to 60°C for 1d. 
The solvent was removed in vacuo and the oily residue was dissolved in H2O (15 mL) and washed 
with Et2O (2 × 25 mL). The aqueous fraction was acidified (pH ~ 1) with 10% HCl and extracted 
with EtOAc (3 × 25 mL). The organic portions were combined, dried and evaporated in vacuo to 
yield a white solid (229.7 mg, 0.85 mmol, 93 %), Rf 0.06 (50% EtOAc:PS). 1H NMR δ 9.16 (bs, 
1H, OH); 7.24-7.35 (m, 3H, ArH), 7.22 (d, J 6.3 Hz, 2H, ArH-o), 6.81 (s, 1H, CH=), 4.49 (ABq, J 
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14.7 Hz, 2H, NCHACHBPh), 3.17-3.23 (m, 2H, CH2-3), 3.11 (ddd, J 18.3, 4.9, 2.2 Hz, 1H, CH-9β), 
3.05 (d, J 16.5, 4.9, 2.2, 1H, CH-6β), 2.56 (d, J 17.1 Hz, 1H, CH-6α), 2.45 (d, J 18.6 Hz, 1H, CH-
9α), 1.92-2.08 (m, 2H, CH2-4). 13C NMR δ 178.1 (C-1), 168.8 (CO2H), 143.5 (CH=), 136.4 (C-7), 
133.9 (ArC-i), 128.9 (ArCH-m), 128.2 (ArCH-o), 127.8 (ArCH-p), 50.7 (C-5), 47.4 (NCH2Ph), 44.1 
(CH2-9), 44.0 (CH2-3), 42.0 (CH2-6), 35.6 (CH2-4). MS (CI) m/z 272 ([MH+], 100%); HRMS (CI) 
Calcd for C16H17NO3 [M+] 271.1208. Found: 271.1123. 
 
(5S*)-2-Benzyl-1-oxo-N-phenyl-2-azaspiro[4.4]non-7-ene-7-carboxamide (25a) 
To a solution of 24 (52.2 mg, 0.21 mmol) and HOBT (26 mg, 0.2 mmol) in dry MeCN (2 mL) at 
0°C, was added aniline (0.02 mL, 0.25 mmol). The solution was stirred for 10 min at 0°C before the 
addition of EDCI (38.2 mg, 0.2 mmol) and left to stir at RT for 15 h and then at 60°C for 2 h. The 
solvent was then removed, and the residue was extracted with DCM and washed successively with 
H2O and brine. The organic portions was then dried and evaporated in vacuo. Purification of the 
crude product was achieved through column chromatography using 70% EtOAc:PS as the eluent to 
yield 25a as white crystals (36.2 mg, 0.11 mmol, 54%), mp. 148-150°C, Rf 0.32 (60% EtOAc:PS). 
1H NMR 1H NMR (500 MHz) δ 7.55 (d, J 8 Hz, 2H, ArH-o), 7.29-7.34 (m, 5H, ArH), 7.23 (d, J 7.5 
Hz, 2H, ArH-m), 7.11 (t, J 7.25 Hz, 1H, ArH-p), 6.50 (s, 1H, CH=), 4.49 (ABq, J 14.5 Hz, 2H, 
NCH2), 3.21 (q, J 7 Hz, 2H, CH2-3), 3.15 (d, J 16 Hz, 1H, CH-6β), 3.08 (d, J 18 Hz, 1H, CH-9β),  
2.68 (d, J 15 Hz, 1H, CH-6α), 2.49 (d, 18 Hz, 1H, CH-9α), 2.00-2.11 (m, 2H, CH2-4). 13C NMR 
(125 MHz) δ 177.6 (C-1), 162.7 (CONHPh), 137.8 (ArC-i), 137.7 (C-7), 136.2 (ArC-i`), 135.0 
(CH=), 128.8 (ArCH), 128.6 (ArCH-m), 127.9(ArCH), 127.5 (ArCH), 124.2 (ArCH-p), 119.9 
(ArCH-o), 50.3 (C-5), 47.1 (NCH2), 43.7 (CH2-3 and CH2-9), 42.4 (CH2-6), 35.3 (CH2-4). MS (CI) 
m/z 347 ([MH+], 80%); HRMS (CI) Calcd for C22H22N2O2 [M+] 346.1681. Found: 346.1632. 
 
Spiro[cyclopentane-1`,3-[3H]indole]-2,3`(1H)-dione (41) and Spiro[cyclopentane-1`,3-
[3H]indole]-2,3`(1H)-dione-1-carboxamide (42) 
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A solution of racemic acid 32 (55.6 mg, 0.24 mmol), diphenylphosphoryl azide (DPPA) (0.11 mL, 
4.8 × 10-4 mol) and NEt3 (0.07 mL, 0.48 mmol) in anhydrous toluene (3 mL) was heated at 85°C for 
3 h. The mixture was then heated at reflux for 30 min then 8.9 M HCl (0.05 mL) was cautiously 
added. The mixture was then heated at reflux for another 1 h before allowing to cool to RT with 
stirring for 15 h. The solvent was removed in vacuo. NMR analysis of the crude mixture revealed a 
1:1 mixture of 41:42, respectively. The crude mixture was purified by column chromatography in 
30-50% EtOAc:PS and then a second time with 2:1:1 (DCM:PS:EtOAc). 41: A semi-crystalline 
yellow oil (26.5 mg, 0.13 mmol, 54%), Rf 0.28 (50% EtOAc:PS). 1H NMR (C6D6, 500 MHz) δ 8.81 
(bs, 1H, NH), 6.96 (t, J 7.8 Hz, 1H, ArH-6), 6.79 (t, J 7.8 Hz, 1H, ArH-5), 6.66 (d, J 7.5 Hz, 1H, 
ArH-4), 6.55 (d, J 7.5 Hz, 1H, ArH-7), 2.53-2.62 (m, 1H, CH-4`α), 2.51 (d, J 17.5 Hz, 1H, CH-2`α), 
2.06-2.15 (m, 1H, CH-4`β), 2.05 (d, J 18 Hz, 1H, CH-2`β), 2.01-2.06 (m, 1H, CH-5`α), 1.60 (dt, J 
13, 8.5 Hz, 1H, CH-5`β). 13C NMR (C6D6, 125 MHz) δ 214.0 (C-3`), 182.7 (C-2), 141.0 (C-7a), 
133.4 (C-3a), 128.4 (ArCH-6), 122.7 (ArCH-5), 122.5 (ArCH-4), 110.3 (ArCH-7), 51.1 (C-3), 46.7 
(CH2-2`), 36.5 (CH2-4`), 33.4 (CH2-5`). MS (EI) m/z 201 ([M+], 67%), 145 ([M+ -(CH2)2CO], 
100%); HRMS (EI) Calcd for C12H12NO2 [MH+] 202.0868. Found: 202.0874. 42: White crystals 
(21.1 mg, 0.086 mmol, 35%), mp. 139-143°C, Rf 0.73 (50% EtOAc:PS). 1H NMR (C6D6, 500 
MHz) δ 8.64 (d, J 8Hz, 1H, ArH-7), 7.96 (bs, 1H, NHAHB), 7.08 (t, J 8Hz, 1H, ArH-6), 6.85 (t, J 
7.5 Hz, 1H, ArH-5), 6.55 (d, J 7.5 Hz, 1H, ArH-4), 4.84 (bs, 1H, NHAHB), 2.37 (ddd, J 18, 9, 9 Hz, 
1H, CH-4`α), 2.22 (d, J 18.5 Hz, 1H, CH-2`α), 2.01 (ddd, J 18.5, 9, 6 Hz, 1H, CH-4`β), 1.87 (d, J 
18.5 Hz, 1H, CH-2`β), 1.68-1.74 (m, 1H, 1H, CH-5`α), 1.37-1.43 (m, 1H, 1H, CH-5`β). 13C NMR 
(C6D6, 125 MHz) δ 212.5 (C-3`), 182.0 (C-2), 152.1 (CONH2), 139.9 (C-7a), 131.5 (C-3a), 128.8 
(ArCH-6), 125.0 (ArCH-5), 121.6 (ArCH-4), 117.0 (ArCH-7), 51.3 (C-3), 47.0 (CH2-2`), 36.1 
(CH2-4`), 34.0 (CH2-5`). LRMS (EI) m/z 244 ([M+], 2%), 201 ([M+ -CONH2], 36%); HRMS (EI) 
Calcd for C13H12N2O3 [M+] 244.0848. Found: 244.0823. 
 
27 
Ethyl (S*)-2-oxo-spiro[3`-cyclopentane-1`,3-[3H]indole]-(3`S*)-carboxylate (43) and Ethyl 
(R*)-2-oxo-spiro[3`-cyclopentane-1`,3-[3H]indole]-(3`R*)-carboxylate (44) 
To a mixture of spiroalkene 15 (34.9 mg, 0.136 mmol) in EtOAc (2.2 mL) was added 10 wt. % 
palladium on activated carbon (9.4 mg). The system was then flushed with H2 gas and left stirring 
under a H2 atmosphere for 15 h. The crude reaction mixture was filtered on celite and washed 
multiple times with EtOAc. These organic extracts were evaporated in vacuo. NMR analysis of 
crude mixture revealed a 1.75:1 (43:44). The crude product was purified by column chromatography 
in 20-30% EtOAc:PS and then further by PTLC in 30% EtOAc:PS.  43: A creamy white oil (20.1 
mg, 0.78 µmol, 57%), Rf 0.28 (30% EtOAc:PS). 1H NMR (500 MHz) δ 8.91 (bs, 1H, NH), 7.20 (t, J 
7.7 Hz, 1H, ArH-6), 7.18 (d, J 7 Hz, 1H, ArH-4), 7.02 (t, J 7.7 Hz, 1H, ArH-5), 6.93 (d, J 7.5 Hz, 
1H, ArH-7), 4.18 (q,  J 7.3 Hz, 2H, CH2CH3), 3.25 (m, 1H, CH-3`β), 2.51 (dd, J 13, 10 Hz, 1H, CH-
2`α), 2.28-2.40 (m, 3H, CH2-4` and CH-5`α), 2.14 (dd, J 13, 8 Hz, 1H, CH-2`β), 1.84-1.95 (m, 1H, 
CH-5`β), 1.28 (t, J 7.3 Hz, 3H, CH3CH2). 13C NMR (125 MHz) δ 183.1 (C-2), 174.4 (CO2Et), 140.1 
(C-7a), 136.1 (C-3a), 127.7 (ArCH-6), 122.53 (ArCH-4), 122.49 (ArCH-5), 109.8 (ArCH-7), 60.6 
(CH2CH3), 54.3 (C-3), 44.8 (CH-3`β), 40.8 (CH2-2`), 37.3 (CH2-5`), 29.6 (CH2-4`), 14.2 (CH3CH2). 
MS (EI) m/z 259 ([M+], 72%), 260 ([MH+], 12%); HRMS (EI) Calcd for C15H17NO3 [M+] 
259.1208. Found: 259.1219.  44: A yellow oil (6.9 mg, 0.26 µmol, 20%), Rf 0.38 (30% EtOAc:PS). 
1H NMR (C6D6, 500 MHz) δ 8.14 (bs, 1H, NH), 7.22 (d, 1H, J 7.5 Hz, ArH-4) 6.96 (dt, J 7.5, 1 Hz, 
1H, ArH-6), 6.86 (dt, J 7.5, 1 Hz, 1H, ArH-5), 6.48 (d, J 8 Hz, 1H, ArH-7), 3.99 (q, J 7 Hz, 2H, 
CH2CH3), 3.38 (ddd, J 16, 16, 8 Hz, 1H, CH-3`α), 2.43 (dd, J 13.5, 8.5 Hz, 1H, CH-2`α), 2.33-2.38 
(m, 1H, CH-4`α), 2.31 (dd, J 14, 8 Hz, 1H, CH-2`β), 2.19-2.25 (m, 1H, CH-4`β), 2.10 (dt, J 13, 7.5 
Hz, 1H, CH-5`α) 1.87 (dt, J 12.5, 7.5 Hz, 1H, CH-5`β), 0.96 (t, J 7 Hz, 3H, CH3CH2). 13C NMR 
(C6D6, 125 MHz) δ 183.6 (C-2), 175.2 (CO2Et), 140.9 (C-7a), 135.6 (C-3a), 123.4 (ArCH-4), 127.7 
(ArCH-6), 122.7 (ArCH-5), 109.5 (ArCH-7), 60.3 (CH2CH3), 54.3 (C-3), 44.5 (CH-3`α), 40.6 (CH2-
2`), 38.1 (CH2-5`), 30.8 (CH2-4`), 14.2 (CH3CH2). LRMS (EI) m/z 259 ([M+], 64%), 260 ([MH+], 
12%); HRMS (EI) Calcd for C15H17NO3 [M+] 259.1208. Found: 259.1220. 
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SUPPORTING INFORMATION 
 
Pages 1-3 X-ray data 
Pages 4-14 Experimental procedures for the synthesis of compounds 25b-37 
X-ray Data 
All single-crystal X-ray structure determinations were executed using full spheres of data from a 
Bruker AXS CCD area-detector instrument (ω-scans) fitted with a monochromatic MoKα radiation 
source (λ = 0.71073 Å) (Exception: 28, which employed synchrotron radiation, λ = 0.5500 Å), 
Nt(otal) reflections merging to N unique (Rint cited) after 'empirical'/multiscan absorption correction 
(proprietary software), No with F > 4σ(F) considered 'observed' and used in the full matrix least 
squares refinement (reflection weights: (σ2(F) + 0.00 nw F
2)-1).  Molecular projections show non-
hydrogen atoms with 50% probability amplitude displacement envelopes, hydrogen atoms having 
arbitrary radii of 0.1 Å.  In all examples containing .CO.NH. components, the hydrogen is involved 
in a hydrogen-bond with that oxygen of a neighbouring molecule. 
Crystal/refinement data: 10.  C16H23NO5, M = 309.4.  Triclinic, space group 1P  (#2), a = 6.085(1), 
b = 9.534(2), c = 14.682(2) Å, α = 79.674(3), β = 80.484(3), γ = 77.536(3)°, V = 811.0 Å
3.  Dc (Z = 
2) = 1.267 g cm
-3.  µMo = 0.09 mm
-1; specimen: 0.27 x 0.20 x 0.12 mm; 'T'min/max = 0.76.  2θmax = 
58°; Nt = 7868, N = 3938 (Rint = 0.025), No = 2934; R = 0.047, Rw = 0.052 (nw = 0.4).  |∆ρmax| = 
0.34(3) e Å-3.  (x,y,z,Uiso)H refined.  T ca. 153 K. (S)-16.  C24H28N2O7S, M = 488.6.  Monoclinic, 
space group P21 (#4), a = 12.085(5), b = 7.243(1), c = 13.924(2) Å, β = 101.040(3)°, V = 1196 Å
3.  
Dc (Z = 2) = 1.356 g cm
-3.  µMo = 0.18 mm
-1; specimen: 0.28 x 0.18 x 0.14 mm; 'T'min/max = 0.89.  
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2θmax = 58°; Nt = 11606, N = 3210 (Rint = 0.025), No = 2241; R = 0.053, Rw = 0.056 (nw = 0.6).  
|∆ρmax| = 0.28(3) e Å
-3.  xabs = 0.06(16).  T ca. 300 K.  22.  C11H15NO3, M = 209.3.  Triclinic, space 
group 1P , a = 5.597(1), b = 7.910(2), c = 12.861(3) Å, α = 86.683(5), β = 79.353(5), γ = 
75.871(5)°, V = 542.6 Å
3.  Dc (Z = 2) = 1.281 g cm
-3.  µMo = 0.09 mm
-1; specimen: 0.63 x 0.12 x 
0.08 mm; 'T'min/max = 0.78.  2θmax = 58°; Nt = 6707, N = 2861 (Rint = 0.027), No = 2274; R = 0.044, 
Rw = 0.051 (nw = 0.3).  |∆ρmax| = 0.36(3) e Å
-3.  T ca. 153 K.  25a.  C22H22N2O2, M = 346.5.  
Orthorhombic, space group Pca21 (#29), a = 24.140(16), b = 7.734(5), c = 9.836(7) Å, V = 1836 Å
3.  
Dc (Z = 4) = 1.253 g cm
-3.  µMo = 0.08 mm
-1; specimen: 0.13 x 0.07 x 0.03 mm; 'T'min/max = 0.76.  
2θmax = 50°; Nt = 13466, N = 1698 (Rint = 0.11), No = 1284; R = 0.066, Rw = 0.090 (nw = 3).  
|∆ρmax| = 0.30(6) e Å
-3.  xabs not refined.  T ca. 153 K.  25b. C24H27N3O2, M = 389.5.  Triclinic, 
space group 1P , a = 8.260(3), b = 10.892(4), c = 12.538(4) Å, α = 67.764(6), β = 82.723(6), γ = 
81.564(6)°, V = 1030 Å3.  Dc (Z = 2) = 1.256 g cm
-3.  µMo = 0.08 mm
-1; specimen: 0.12 x 0.08 x 
0.04 mm; 'T'min/max = 0.88.  2θmax = 50°; Nt = 9351, N = 3586 (Rint = 0.046), No = 2207; R = 0.057, 
Rw = 0.072 (nw = 0.2).  |∆ρmax| = 0.32(4) e Å
-3.  T ca. 153 K.  27.  C15H10N2O2, M = 256.3.  
Monoclinic, space group P21/c (#14), a = 8.204(2), b = 18.128(5)), c = 8.914(2) Å, β = 107.823(4)°, 
V = 1262 Å3.  Dc (Z = 4) = 1.349 g cm
-3.  µMo = 0.09 mm
-1; specimen: 0.12 x 0.08 x 0.08 mm; 
'T'min/max = 0.92.  2θmax = 50°; Nt = 10582, N = 2207 (Rint = 0.065), No = 1747; R = 0.056, Rw = 
0.081 (nw = 2).  |∆ρmax| = 0.30(5) e Å
-3.  T ca. 153 K. 28.  C11H15NO3, M = 209.3.  Monoclinic, 
space group P21/c, a = 14.2396(11), b = 6.2065(5), c = 11.9144(9) Å, β = 102.276(4)°, V = 1029 
Å3.  Dc (Z = 4) = 1.351 g cm
-3.  µMo = 0.06 mm
-1; specimen: not recorded; 'T'min/max = 1.00.  2θmax 
= 45°; Nt = 28315, N = 2908 (Rint = 0.97), No = 2306; R = 0.043, Rw = 0.052 (nw = 0.8).  |∆ρmax| = 
0.49(4) e Å-3. (x,y,z,Uiso)H refined.  T ca. 120 K. 30. C16H17NO3, M = 271.3.  Orthorhombic, space 
group Pbca (# 61), a = 11.667(7), b = 10.836(6), c = 21.167(12) Å, V = 2676 Å3.  Dc (Z = 8) = 
1.347 g cm
-3.  µMo = 0.09 mm
-1; specimen: 0.13 x 0.06 x 0.03 mm; 'T'min/max = 0.00.  2θmax = 50°; 
Nt = 20960, N = 2394 (Rint = 0.16), No = 975; R = 0.087, Rw = 0.011 (nw = 4.5).  |∆ρmax| = 0.36(5) e 
Å-3.  Comment.  The carboxylate group was modelled as disordered over a pair of sites set at equal 
occupancy after trial refinement; the associated hydrogen bonding interactions appear to be with the 
C=O group oxygen of a neighbouring molecule. 31. C22H22N2O2, M = 346.4.  Triclinic, space 
group 1P , a = 5.121(1), b = 9.606(1), c = 12.379(1) Å, α = 69.657(3), β = 81.925(3), γ = 
34 
74.622(3)°, V = 871.8 Å
3.  Dc (Z = 2) = 1.320 g cm
-3.  µMo = 0.09 mm
-1; specimen: 0.25 x 0.22 x 
0.04 mm; 'T'min/max = 0.89.  2θmax = 65°; Nt = 12099, N = 6128 (Rint = 0.025), No = 4580; R = 
0.055, Rw = 0.077 (nw = 3.5).  |∆ρmax| = 0.53(3) e Å
-3.  41. C12H11NO2, M = 201.2.  Triclinic, space 
group 1P , a = 6.667(4), b = 10.528(6), c = 14.730(8) Å, α = 105.632(9), β = 98.876(10), γ = 
90.305(10)°, V = 983 Å3.  Dc (Z = 4) = 1.360 g cm
-3.  µMo = 0.09 mm
-1; specimen: 0.13 x 0.11 x 
0.03 mm; 'T'min/max = 0.74.  2θmax = 50°; Nt = 9300, N = 3355 (Rint = 0.25), No = 1645; R = 0.12, Rw 
= 0.25 (nw = 2.5).  |∆ρmax| = 1.2(2) e Å
-3.  Comment.  The conformations of the two C5 rings differ 
slightly, the torsions being 'flat' in the bonds to either side of the CO group respectively.  42.  
C13H12N2O3, M = 244.3.  Monoclinic, space group P21/n (#14), a = 16.203(3), b = 6.373(3), c = 
29.233(2) Å, β = 90.207(7)°, V = 1156 Å3.  Dc (Z = 4) = 1.404 g cm
-3.  µMo = 0.10 mm
-1; specimen: 
0.50 x 0.10 x 0.04 mm; 'T'min/max = 0.89.  2θmax = 52°; Nt = 7690, N = 2009 (Rint = 0.043), No = 
1528; R = 0.059, Rw = 0.096 (nw = 6).  |∆ρmax| = 0.62(4) e Å
-3.  T ca. 153 K. 
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(5S*)-2-Benzyl-1-oxo-N-(o)-N,N-dimethylphenyl-2-azaspiro[4.4]non-7-ene-7-carboxamide 
(25b) 
The title compound was prepared from 24 (48.5 mg, 0.18 mmol) and N,N-dimethylaminoaniline 
(26.8 mg, 0.2 mmol) using a similar method to that described for the above synthesis of 25a, 
however the reaction mixture was allowed to stir under N2 at RT for 15 h. The crude compound was 
purified by column chromatography in 70% EtOAc:PS to yield brown crystals (44.4 mg, 0.11 
mmol, 64%), mp. 168-170°C, Rf 0.30 (70% EtOAc:PS). 1H NMR (500 MHz) δ 7.39 (d, J 8.5 Hz, 
2H, ArH-o`), 7.34 (t, J 7.3 Hz, 2H, ArH-m), 7.29 (t, J 7 Hz, 2H, ArH-p), 7.23 (d, J 7 Hz, 2H, ArH-
o), 6.70 (d, J 9 Hz, 2H, ArH-m`), 6.47 (bs, 1H, CH=), 4.49 (ABq, J 15 Hz, 2H, NCHACHBPh), 3.20 
(q, J 6.3 Hz, 2H, CH2-3), 3.14 (dd, J 15.5, 2.5 Hz, 1H, CH-6β), 3.08 (dd, J 18, 2.5 Hz, 1H, CH-9β), 
2.92 (bs, 6H, N(CH3)2), 2.66 (d, J 15.5 Hz, 1H, CH-6α), 2.47 (d, J 17.5 Hz, 1H, CH-9α), 2.10-1.99 
(m, 2H, CH2-4). 13C NMR δ 178.1 (C-1), 148.3 (ArC-p`), 138.2 (C-7), 136.6 (ArC-i), 134.8 (CH=), 
129.0 (ArCH-m), 128.3 (ArCH-o), 127.9 (ArCH-p), 127.7 (ArC-i`), 122.0 (ArCH-o`), 113.2 
(ArCH-m`), 50.7 (C-5), 47.3 (NCH2Ph), 43.9 (CH2-3), 43.8 (CH2-9), 42.6 (CH2-6), 41.1 (N(CH3)2), 
35.5 (CH2-4). MS (CI) m/z 390 ([MH+], 100%); HRMS (CI) Calcd for C24H28N3O2 [MH+] 
390.2181. Found: 390.2170. 
 
(5S*)-1-Oxo-2-azaspiro[4.4]non-7-ene-7-carboxylic acid (26) 
The title compound was prepared from 22 (90.5 mg, 0.43 mmol) using a similar method to that 
described above for the synthesis of 24. Compound 26 was obtained as brown crystals (41.6 mg, 
0.23 mmol, 53%), mp. 168°C, Rf 0.03 (EtOAc). 1H NMR δ 6.79 (bs, 1H, NH), 6.68 (s, 1H, CH=), 
3.68-3.76 (m, 2H, NCH2), 3.03 (overlapping d, J 14.4 Hz, 2H, CH-6β, CH-9β), 2.59 (d, J 15 Hz, 1H, 
CH-6α), 2.47 (d, J 18 Hz, 1H, CH-9α), 2.04-2.21 (m, 2H, CH2-4). 13C NMR δ 181.7 (C-1), 165.0 
(CO2H), 141.2 (CH=), 134.1 (C-7), 49.4 (C-5), 43.7 (CH2-9), 42.1 (CH2-6), 39.5 (NCH2), 37.9 
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(CH2-4). MS (CI) m/z 182 ([MH+], 100%); HRMS (CI) Calcd for C9H12NO3 [MH+] 182.0817. 
Found: 182.0818. 
 
(5S*)-1-Oxo-N-phenyl -2-azaspiro[4.4]non-7-ene-7-carboxamide (27) 
The title compound was prepared by two methods. Method 1: The title compound was prepared 
from 26 (38 mg, 0.21 mmol) and aniline (0.02 mL, 0.22 mmol) using a similar method to that 
described above for the synthesis of 25a. Compound 27 was obtained as a yellow solid, mp. 148-
150 °C after purification by column chromatography in 5% MeOH:EtOAc (48.9 mg, 1.91 × 10-4 
mol, 91%), Rf 0.23 (5% MeOH:EtOAc). Method 2: To a solution of spiroamide 35 (75.7 mg, 0.16 
mmol) was added anisole (0.18 mL, 1.65 mmol) and TFA (1.5 mL). The reaction was left to stir for 
15 h. The volatiles were then removed and residue dissolved in CHCl3 (10 mL) and poured slowly 
onto sat. Na2CO3 solution. The mixture was repeatedly extracted with CHCl3 to yield a yellow oil 
(23.1 mg, 0.09 mmol, 57%). 1H NMR δ 7.55 (d, J 9 Hz, 2H, ArH), 7.26-7.35 (m, 2H, ArH), 7.10 (t, 
J 7.3 Hz, 1H, ArH), 6.50 (s, 1H, CH=), 6.15 (bs, 1H, CONHPh), 3.37 (t, J 6.6 Hz, 2H, NCH2), 3.14 
(dd, J 15.7, 2.5 Hz, 1H, CH-6β), 3.05 (dd, J 18.1, 2.5 Hz, 1H, CH-9β), 2.71 (d, J 16.2 Hz, 1H, CH-
6α), 2.52 (d, J 18.3 Hz, 1H, CH-9α), 2.08-2.26 (m, 2H, CH2-4). 13C NMR δ 183.0 (C-1), 166.0 
(CO2NHPh), 137.7 (C-7), 134.9 (CH=), 130.3 (ArC-i), 128.8 (ArCH-m), 124.2 (ArCH-p), 119.8 
(ArCH-o), 49.1 (C-5), 43.3 (CH2-9), 42.1 (CH2-6), 39.2 (NCH2), 37.4 (CH2-4). MS (CI) m/z 257 
([MH+], 32%); HRMS (CI) Calcd for C15H16N2O2 [M+] 256.1212. Found: 256.1227. 
 
Ethyl (5R*)-1-oxo-2-azaspiro[4.4]non-6-ene-6-carboxylate (28) 
The title compound was prepared from 10 (337.8 mg, 1.09 mmol) in dry DCM (1 mL) and the 
addition of TFA (1 mL) as described for the above synthesis of 22. The organic portions were dried, 
and evaporated in vacuo to yield compound 28 as white needle-like crystals (197.0 mg, 0.94 mmol, 
86%), mp. 102-104°C, Rf 0.13 (70% EtOAc:PS). 1H NMR δ 6.99 (t, J 2.7 Hz, 1H, CH=), 4.18 (q, J 
7.2 Hz, 2H, CH2CH3), 3.50 (ddt, J 9.3, 3.6, 0.9 Hz, 1H, NCHACHB), 3.35 (dt, J 9.3, 7.8 Hz, 1H, 
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NCHACHB), 2.68 ( ddd, J 9.3, 4.5, 2.7 Hz, 1H, CHACHB-8), 2.62 (ddd, J 9.3, 4.2, 2.7 Hz, 1H, 
CHBCHA-8), 2.59-2.46 (m, 1H, CHACHB-4), 2.44-2.37 (m, 1H, CHACHB-9), 2.09-2.01 (m, 1H, 
CHBCHA-4), 1.99 (ddd, 12.6, 8.1, 4.5 Hz, 1H, CHBCHA-9), 1.28 (ddt, 3H, J 7.2, 7.2, 3 Hz, 3H, 
CH2CH3). 13C NMR (125 MHz) δ 180.9 (C-1), 163.7 (CO2Et), 147.0 (CH=), 137.8 (C-6), 60.1 
(CH2CH3), 55.8 (C-5), 39.7 (NCH2), 36.4 (CH2-9), 32.9 (CH2-4), 31.2 (CH2-8), 14.0 (CH2CH3). MS 
(CI) m/z 210 ([MH+], 53%); HRMS (CI) Calcd for C11H16NO3 [MH+] 210.1130. Found: 210.1133. 
 
Ethyl (5R*)-2-benzyl-1-oxo-2-azaspiro[4.4]non-6-ene-6-carboxylate (29) 
The title compound was prepared from 28 (129 mg, 0.62 mmol) as described for the synthesis of 23 
however the reaction mixture was left stirring for 5 h. The crude product was purified by column 
chromatography using 50% EtOAc:PS as the eluent to give a 29 as a yellow oil (87.3 mg, 0.3 mmol, 
47%), Rf 0.42 (50% EtOAc:PS). 1H NMR δ 7.23-7.36 (m, 5H, ArH), 6.99 (t, J 2.5 Hz, 1H, CH=), 
4.50 (ABq, J 17.4 Hz, 2H, NCHACHBPh), 4.08-4.23 (m, 2H, CH2CH3), 3.35 (dt, J 9.4, 3.9 Hz, 1H, 
CHACHB-3), 3.21 (ddd, J 9.3, 8.4, 6.9 Hz, 1H, CHBCHA-3), 2.61-2.73 (m, 1H, CHACHB-8), 2.55 
(ddd, J 8.7, 6.3, 2.4 Hz, 1H, CHBCHA-8), 2.33-2.46 (om, 2H, CHACHB-9 and CHACHB-4), 1.89-
2.00 (m, 2H, CHBCHA-9 and CHBCHA-4), 1.22-1.29 (m, 3H, CH2CH3). 13C NMR δ 176.9 (C-1), 
163.8 (CO2Et), 147.0 (CH=), 138.3 (C-7), 136.6 (ArC-i), 128.5 (ArCH-m), 128.0 (ArCH-o), 127.3 
(ArCH-p), 60.2 (CH2CH3), 56.7 (C-5), 47.0 (NCH2Ph), 44.2 (CH2-3), 36.9 (CH2-9), 31.2 (CH2-8), 
30.5 (CH2-4), 14.1 (CH2CH3). MS (CI) m/z 300 ([MH+], 8%); HRMS (EI) Calcd for C18H21NO3 
[M+] 299.1521. Found: 299.1508. 
  
(5R*)-2-Benzyl-1-oxo-2-azaspiro[4.4]non-6-ene-6-carboxylic acid (30) 
The title compound was prepared from 29 (87.3 mg, 0.3 mmol) as described for the synthesis of 24 
to yield white needle-like crystals (63.3 mg, 0.23 mmol, 80%) which were purified by 
recrystallisation from 1% MeOH:EtOAc to yield white needle-like crystals (22.2 mg, 82 µmol, 
28%), mp. 200°C. 1H NMR (CD3OD, 500 MHz) δ 7.25-7.34 (m, 5H, ArH), 6.99 (t, J 2.5 Hz, 1H, 
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CH=), 4.48 (ABq, J 14.7 Hz, 2H, NCHACHBPh), 3.25-3.39 (m, 2H, CH2-3), 2.59 (dt, J 7.25, 2.5 
Hz, 1H, CH2-8), 2.37 (ddd, J 13, 9, 8 Hz, 1H, CHACHB-4), 2.28 (ddd, J 12.5, 8.75, 8.5 Hz, 1H, 
CHACHB-9), 2.00-2.08 (m, 2H, CHBCHA-9 and CHBCHA-4). 13C NMR (CD3OD, 125 MHz) δ 180.0 
(C-1), 167.7 (CO2H), 148.6 (CH=), 137.6 (C-7), 139.9 (ArC-i), 129.7 (ArCH-m), 128.9 (ArCH-o), 
128.6 (ArCH-p), 58.8 (C-5), 47.8 (NCH2Ph), 45.6 (CH2-3), 37.3 (CH2-9), 32.1 (CH2-8), 31.4 (CH2-
4). MS (CI) m/z 272 ([MH+], 100%); HRMS (CI) Calcd for C16H17NO3 [M+] 271.1208. Found: 
271.1123. 
 
(5R*)-2-Benzyl-1-oxo-N-phenyl-2-azaspiro[4.4]non-6-ene-6-carboxamide (31) 
The title compound was prepared from 30 (22.2 mg, 82 μmol) as described for the synthesis of 25a 
however the reaction mixture was left stirring at 60°C for 2d and then another equivalent of EDCI 
(16.2 mg, 82 μmol) was added and the reaction was left to stir for 60°C for 4d under N2. The crude 
product was purified by column chromatography using 60-100% EtOAc:PS to yield white crystals 
(27.4 mg, 79 μmol, 97%), mp. 164-165°C, Rf 0.18 (60% EtOAc:PS). 1H NMR δ 8.38 (bs, 1H, NH), 
7.52 (d, J 7.5 Hz, 2H, ArH-o`), 7.24-7.29 (m, 7H, ArH), 7.06 (t, J 7.35 Hz, 1H, ArH-p), 6.68 (bs, 
1H, CH=), 4.53 (ABq, J 14.7 Hz, 2H, NCHACHBPh), 3.39 (dt, J 9.3, 3 Hz, 1H, CHACHB-3), 3.24 
(dd, J 17.4, 7.8 Hz, 1H, CHBCHA-3), 2.54-2.62 (m, 2H, CH2-8), 2.49 (dt, J 12, 8.4 Hz, 1H, 
CHACHB-4), 2.34 (ddd, 12.6, 9, 8.1 Hz, 1H, CHACHB-9), 1.93-2.01 (om, 2H, CHBCHA-9 and 
CHBCHA-4). 13C NMR δ 177.9 (C-1), 163.6 (CONHPh), 142.4 (C-7), 139.9 (CH=), 138.3 (ArC-i`), 
136.5 (ArC-i), 129.0 (ArCH), 128.9 (ArCH), 128.1 (ArCH), 127.7 (ArCH-p), 124.2 (ArCH-p`), 
120.2 (ArCH-o’), 58.8 (C-5), 47.4 (NCH2Ph), 44.7 (CH2-3), 36.4 (CH2-9), 31.3 (CH2-8), 30.7 
(CH2-4). MS (CI) m/z 347 ([MH+], 57%), 346 ([M+], 26%), 225 ([M+ -CONHPh], 17%), 149 ([M+ -
(CONHPh, Ph)], 45%); HRMS (CI) Calcd for C22H22N2O2 [M+] 346.1681. Found: 346.1671. 
 
2-Oxo-spiro[3`-cyclopentene-1`,3-[3H]indole]-3`-carboxylic acid (32)  
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The title compound was prepared from 15 (34.7 mg, 0.14 mmol) using a similar method to that 
described for the synthesis of 24. However the mixture was left stirring at 60°C for 5 h and no 
further additions of K2CO3 were needed. After extraction, the compound required no further 
purification yielding a creamy brown solid (29.9 mg, 0.13 mmol, 94%), mp. 108-110°C, Rf 0.38 
(EtOAc). 1H NMR δ 9.13 (bs, 1H, NH), 7.23 (d, J 7.8 Hz, 1H, ArH-4), 7.22 (t, J 7.6 Hz, 1H, ArH-
6), 7.03 (t, J 7.6 Hz, 1H, ArH-5), 6.98 (s, 1H, CH=), 6.94 (d, J 7.5Hz, 1H, ArH-7), 3.28 (dd, J 16.5, 
2.7 Hz, 1H, CH-2`α), 3.22 (dd, J 16.5 Hz, 2.1Hz, 1H, CH-5`α), 2.91 (d, J 16.5 Hz, 1H, CH-2`β), 
2.83 (d, J 18.9 Hz, 1H, CH-5`β).13C NMR δ 183.6 (C-2), 168.5 (CO2H), 143.1 (CH=), 139.5 (C-7a), 
136.4 (C-3a), 134.4 (C-3`), 128.2 (ArCH-6), 123.3 (ArCH-5), 122.1 (ArCH-4), 110.1 (ArCH-7), 
52.7 (C-3), 45.0 (CH2-5`), 43.0 (CH2-2`). MS (EI) m/z 229 ([M+], 12%), 211 ([M+ -H2O], 6%), 183 
([M+- COOH], 14%); HRMS (EI) Calcd for C13H11NO3 [M+] 229.0739. Found: 229.0744. 
 
2-Oxo-N-phenyl-spiro[3`-cyclopentene-1`,3-[3H]indole]-3`-carboxamide (33a) 
The title compound was prepared using two methods. Method 1: The title compound was prepared 
from 32 (29.3 mg, 0.13 mmol) and aniline (0.02 mL, 0.22 mmol) using a similar method to that 
described for the above synthesis of 25a, however the reaction mixture was allowed to stir under N2 
at RT for 15 h. The crude compound was extracted with DCM, and washed with water and brine. 
The organic extracts were dried with MgSO4 and solvent evaporated in vacuo to yield white crystals 
(35.8 mg, 0.12 mmol, 92%), mp. 184°C, Rf 0.13 (40% EtOAc:PS). Method 2: To a solution of the 
amide 37 (12.4 mg, 0.029 mmol) in dry DCM was added sequentially anisole (0.03 mL, 0.3 mmol) 
and TFA (0.28 mL, 3.6 mmol). The reaction was left stirring for 15 h. The volatiles were then 
removed, residue dissolved in CHCl3 and poured slowly onto a saturated Na2CO3 solution. The 
crude mixture was repeatedly extracted with CHCl3. The solvent was evaporated in vacuo to yield 
white crystals (4.6 mg, 1.5 × 10-5 mol, 52%), mp. 184°C. 1H NMR δ 8.87 (bs, 1H, NH), 7.78 (bs, 
1H, CONHPh), 7.58 (d, J 8.1Hz, 2H, ArH-o), 7.32 (t, J 7.8Hz, 2H, ArH-m), 7.24 (d, J 7.8Hz, 1H, 
ArH-4), 7.20 (t, J 7.2Hz, 1H, ArH-6), 7.10 (t, J 7.5Hz, 1H, ArH-p), 7.01 (t, J 7.6Hz, 1H, ArH-5), 
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6.91 (d, J 7.8Hz, 1H, ArH-7), 6.68 (s, 1H, CH=), 3.32 (dd, J 16, 2.1Hz, 1H, CH-2`α), 3.18 (d, J 
18.3, 2.1Hz, 1H, CH-5`α), 3.00 (d, J 16.2Hz, 1H, CH-2`β), 2.82 (d, J 18Hz, 1H, CH-5`β). 13C NMR 
δ 182.9 (C-2), 162.5 (CONH), 139.7 (C-7a), 138.2 (C-3`), 137.6 (ArC-i), 136.1 (C-3a), 135.6 
(CH=), 129.0 (ArCH-m), 128.2 (ArCH-6), 124.4 (ArCH-p), 123.2 (ArCH-5), 122.3 (ArCH-4), 
120.1 (ArCH-o), 109.9 (ArCH-7), 52.5 (C-3), 44.8 (CH2-5`), 43.5 (CH2-2`). MS (EI) m/z 304 ([M+], 
8%), 184 ([M+-CONHPh], 92%), 159 [M+-CONHPhC=CH], 97%); HRMS (EI) Calcd for 
C19H16N2O2 [M+] 304.1212. Found: 304.1207. 
 
2-Oxo-N-(o)-N,N-dimethylphenyl-spiro[3`-cyclopentene-1`,3-[3H]indole]-3`-carboxamide 
(33b) 
The title compound was prepared from 32 (23.8 mg, 0.1 mmol) and N,N-dimethylaminoaniline 
(24.1 mg, 0.2 mmol) using a similar method to that described for the above synthesis of 33a, 
however the reaction mixture was allowed to stir under N2 at RT 15 h. The crude compound was 
purified by column chromatography using 50-70% EtOAc:PS to yield a black powder (15.9 mg, 45 
µmol, 44%), Rf 0.73 (80% EtOAc:PS). 1H NMR δ 8.35 (bs, 1H, NH-1), 7.40 (d, J 9.3 Hz, 2H, ArH-
o), 7.40 (bs, 1H, NHPhNMe2), 7.26 (d, J 7.2 Hz, 1H, ArH-4), 7.20 (dt, J 7.5, 1.5 Hz, 1H, ArH-6), 
7.02 (dt, J 7.5, 0.9 Hz, 1H, ArH-5), 6.90 (d, J 7.5 Hz, 1H, ArH-7), 6.69 (d, J 9 Hz, 2H, ArH-m), 
6.64 (bs, 1H, CH=), 3.33 (dd, J 16, 2.2 Hz, 1H, CH-2`α), 3.19 (dq, J 18, 2.4 Hz, 1H, CH-5`α), 2.98 
(d, J 15.9 Hz, 1H, CH-2`β), 2.91 (bs, 6H, N(CH3)2), 2.82 (d, J 17.4 Hz, 1H, CH-5`β). 13C NMR δ 
182.6 (C-2), 162.1 (=CCO), 148.1 (ArC-p), 139.6 (C-7a), 138.3 (C-3`), 136.4 (C-3a), 135.0 (CH=), 
128.2 (ArCH-6), 127.3 (ArC-i), 123.1 (ArCH-5), 122.4 (ArCH-4), 121.9 (ArCH-o), 112.9 (ArCH-
m), 109.8 (ArCH-7), 52.6 (C-3), 44.9 (CH2-5`), 43.6 (CH2-2`), 40.8 (N(CH3)2). MS (EI) m/z 347 
([M+], 3%), 167 (35%), 149 (100%); HRMS (EI) Calcd for C21H21N3O2 [M+] 347.1634. Found 
347.1633. 
 
N-(4-Methoxybenzyl)-N-phenyl but-2-ynamide (7c)  
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The title compound was prepared from N-(4-methoxybenzyl)-N-phenylamine (117 mg, 0.6 mmol) 
and 2-butynoic acid (50.7 mg, 0.6 mmol) using a similar method to that described for the synthesis 
of 25a. However the reaction mixture was left stirring RT for 15 h. The crude product was purified 
by gradient column chromatography using 10-50% EtOAc:PS as the eluent to yield 7c as a brown 
oil (296.5 mg, 1.06 mmol, 66%), Rf 0.62 (50% EtOAc:PS). 1H NMR δ 7.29-7.31 (m, 2H, ArH-m), 
7.11 (d, J 8.7 Hz, 2H, ArH-o`), 7.04-7.07 (m, 1H, ArH-p), 7.06 (d, J 7.8 Hz, 2H, ArH-o), 6.78 (d, J 
8.7 Hz, 2H, ArH-m`), 4.86 (s, 2H, NCH2), 3.77 (s, 3H, OCH3), 1.70 (s, 3H, CCH3). 13C NMR δ 
158.9 (ArC-p`), 154.3 (CONH), 141.6 (ArC-i), 130.1 (ArCH-o`), 129.0 (ArC-i`), 128.8 (ArCH-m), 
128.4 (ArCH-o), 127.8 (ArCH-p), 113.7 (ArCH-m`), 90.3 (C≡CCH3), 74.1 (C≡CCH3), 55.0 
(OCH3), 51.5 (NCH2), 3.68(CCH3). MS (ES) m/z 280.2 ([MH+], 99%); HRMS (EI) Calcd for 
C18H17NO2 [M+] 279.1259. Found: 279.1280. 
 
(5S*)-2-tert-Butoxycarbonyl-N-phenyl-N-(4-methoxybenzyl)-1-oxo-2-azaspiro[4.4]non-7-ene-7-
carboxamide (35) 
The title compound was prepared using a similar method described above for the synthesis of 9 and 
10 from 4 (190 mg, 0.97 mmol) and 7c (296.5 mg, 1.06 mmol) instead of ethyl 2-butynoate. The 
crude compound was then purified by gradient column chromatography using 10-90% EtOAc:PS as 
eluent to yield 35 as a brown oil (64.3 mg, 0.13 mmol, 14%), Rf 0.59 (50% EtOAc:PS). 1H NMR 
(500 MHz) δ 7.22-7.33 (m, 3H, ArH-m and ArH-p), 7.13 (d, J 7 Hz, 2H, ArH-o`), 6.97 (dd, J 8.5, 
2H, ArH-o), 6.78 (d, J 9 Hz, 2H, ArH-m`), 5.56 (s, 1H, CH=), 4.89 (s, 2H, NCH2), 3.77 (s, 3H, 
OCH3), 3.50-3.58 (m, 2H, CH2-3), 2.74 (d, J 18 Hz, 1H, CH-9β), 2.73 (d, J 14.7 Hz, 1H, CH-6β), 
2.26 (d, J 14.4 Hz, 1H, CH-6α), 2.18 (d, J 18.3 Hz, 1H, CH-9α), 1.71-173 (m, 2H, CH2-4), 1.52 (s, 
9H, C(CH3)3). 13C NMR δ 177.0 (C-1), 166.2 (CONPhPMB), 158.7 (ArC-p`), 150.2 (NCO2), 142.5 
(ArC-i), 136.5 (C-7), 135.1 (CH=), 129.9 (ArCH-o`), 129.3 (ArC-i`), 129.1 (ArCH-m), 127.9 
(ArCH-o), 127.5 (ArCH-p), 113.6 (ArCH-m`), 82.8 (C(CH3)3, 55.1 (OCH3), 52.9 (NCH2), 51.5 (C-
5), 43.8 (CH2-9), 43.1 (CH2-6), 43.0 (CH2-3), 33.2 (CH2-4), 27.9 C(CH3)3. MS (ES) m/z 499 ([MH+ 
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+ Na+], 12%), 477.3 ([MH+], 12%), 377.3 ([MH+ -(Boc, CH3)], 100%); HRMS (ES) Calcd for 
C28H33N2O5 [MH+] 477.2389. Found: 477.2412. 
 
Methyl 3-[(4-Methoxyphenyl)phenylcarbamoyl]-1-(2-nitrophenyl)-cyclopent-3-enecarboxylate 
(36) 
To a solution of alkene 6 (26 mg, 0.12 mmol) and amide 7c (39.1 mg, 0.14 mmol) in dry benzene (3 
mL) was slowly added tributylphosphine (0.02 mL, 80 μmol). The reaction was left to stir for 2d. 
Upon evaporation in vacuo of volatiles the resulting crude product was purified by column 
chromatography using 30-50% EtOAc:PS as eluent to yield a yellow oil (33.4 mg, 0.069 mmol, 
55%), Rf 0.65 (40% EtOAc:PS). 1H NMR (C6D6, 500 MHz) δ 7.52 (d, J 8 Hz, 1H, ArH-3), 7.25 (d, 
J 8.5 Hz, 2H, ArH-o`), 7.10 (d, J 8.5 Hz, 1H, ArH-6), 6.90 (t, J 7.5 Hz, 1H, ArH-5), 6.86-6.88 (m, 
3H, ArH-m and ArH-p), 6.72-6.74 (m, 4H, ArH-m` and ArH-o), 6.67 (t, J 7.7 Hz, 1H, ArH-4), 5.44 
(s, 1H, CH=), 4.94 (ABq, J 14.5 Hz, 2H, NCH2), 3.54 (dd, J 17, 2 Hz, 1H, CH-2`α), 3.32 (dd, J 18.5 
Hz, 1H, CH-5`α), 3.28 (s, 6H, CO2CH3 and OCH3), 3.18 (d, J 17.5 Hz, 1H, CH-2`β), 2.45 (d, J 18.5 
Hz, 1H, CH-5`β). 13C NMR (C6D6, 125 MHz) δ 173.8 (CO2Me), 165.7 (CON), 159.5 (ArC-p`), 
148.8 (ArC-2), 143.2 (ArC-i), 138.7 (ArC-1), 137.1 (C-3`), 134.7 (CH=), 132.7 (ArCH-5), 130.6 
(ArCH-o`), 130.1 (ArC-i`), 129.2 (ArCH-m), 128.7 (ArCH-6), 128.3 (ArCH-o), 127.5 (ArCH-4), 
127.2 (ArCH-p), 125.1 (ArCH-3), 114.1(ArCH-m`), 55.4 (C-1`), 54.6 (CO2CH3), 53.1 (NCH2), 51.9 
(OCH3), 47.0 (CH2-2`), 45.9 (CH2-5`). MS (ES) m/z 487 (15%) [MH+], 455 (18%) [M+ - OMe]; 
HRMS (ES) Calcd for C28H27N2O6 [MH+] 487.1869. Found 487.1871. 
 
2-Oxo-N-phenyl-N-(4-methoxybenzyl)-spiro[3`-cyclopentene-1`,3-[3H]indole]-3`-carboxamide 
(37) 
To a stirred solution of 36 (87.8 mg, 0.18 mmol) in acetic acid (15 mL) was added activated Zn dust 
(40 mg, 0.61 mmol). After 1.5 h, the solution was filtered through celite and the filtrate was then 
washed with sat. Na2CO3 solution and then extracted with EtOAc to yield 37 as a brown oil (12.4 
43 
mg, 0.029 mmol, 16%, Rf= 0.63 in 70% EtOAc:PS). 1H NMR (C6D6, 500 MHz) δ 7.99 (bs, 1H, 
NH), 7.26 (d, J 8.5 Hz, 2H, ArH-o`), 6.96 (t, J 7.5 Hz, 2H, ArH-m), 6.94 (t, J 6.5 Hz, 1H, ArH-6), 
6.88-6.90 (m, 1H, ArH-p), 6.88 (d, J 7 Hz, 1H, ArH-4), 6.81 (d, J 7.5 Hz, 2H, ArH-o), 6.77 (t, J 7.8 
Hz, 1H, ArH-5), 6.74 (d, J 8.5 Hz, 2H, ArH-m`), 6.43 (d, J 8 Hz, 1H, ArH-7), 5.69 (s, 1H, CH=), 
4.95 (ABq, J 14 Hz, 2H, NCH2), 3.29 (s, 3H, OCH3), 3.23 (dd, J 16, 2.5 Hz, 1H, CH-2`α), 2.88 (dd, 
J 18, 2.5 Hz, 1H, CH-5`α), 2.71 (d, J 16.5 Hz, 1H, CH-2`β), 2.18 (d, J 17.5 Hz, 1H, CH-5`β). 13C 
NMR (C6D6, 125 MHz) δ 182.0 (C-2), 165.9 (CON), 159.5 (ArC-p`), 143.4 (ArC-i), 140.4 (C-7a), 
138.3 (C-3`), 137.1 (C-3a), 135.3 (CH=), 130.6 (ArCH-o`), 130.3 (ArC-i`), 129.3 (ArCH-m), 128.5 
(ArCH-o), 128.3 (ArCH-6), 127.2 (ArCH-p), 122.6 (ArCH-5), 122.3 (ArCH-4), 114.1 (ArCH-m`), 
109.6 (ArCH-7), 54.6 (CH3), 53.1 (NCH2), 52.5 (C-3), 46.0 (CH2-2`), 44.8 (CH2-5). MS (CI) m/z 
425 ([MH+], 37%); HRMS (EI) Calcd for C27H24N2O3 [M+] 424.1787. Found: 424.1786. 
 
 
